Image credit- law.com
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, recently announced the release of a range of anti-vedolizumab antibodies.
Vedolizumab (Entyvio) is a monoclonal antibody that is used to treat ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Bio-Rad’s anti-vedolizumab antibodies, which support research into the treatment of these diseases, include four recombinant monoclonal anti-idiotypic antibodies that are highly specific for the humanized IgG1 kappa antibody drug, vedolizumab, and are suitable for development of bioanalytical and patient monitoring assays.
Bio-Rad’s recombinant monoclonal anti-vedolizumab antibodies are generated using the Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display, resulting in highly targeted reagents. The paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. The recombinant production method ensures a consistent and secure supply.
